Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2009-11-03
2011-10-04
Minnifield, Nita M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
Reexamination Certificate
active
08029807
ABSTRACT:
The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally downregulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.
REFERENCES:
patent: 2004/0126389 (2004-07-01), Berthet et al.
patent: 2004014418 (2004-02-01), None
Steeghs et al. (Infect. Immun., 67:4988-4993, 1999).
Braun et al.; “Imp/OstA is required for cell envelope biogenesis inEscherichia coli”; Molecular Microbiology; 2002; vol. 45, No. 5; pp. 1289-1302.
Steeghs et al.; “Meningitis bacterium is viable without endotoxin”; Nature; 1998; vol. 392, No. 6675; pp. 449-450.
Bos et al.; “Identification of an outer membrane protein required for the transport of lipopolysaccharide to the bacterial cell surface”; Proceedings of the National Academy of Sciences; 2004; vol. 101, No. 25; pp. 9417-9422.
Morley et al.; “Vaccine prevention of meningococcal disease, coming soon?”; Vaccine; 2001; vol. 20, Nos. 5-6; pp. 666-687.
Genevrois et al.; “The Omp85 Protein ofNeisseria meningitidisis required for lipid export to the outer membrane”; EMBO Journal; 2003; vol. 22, No. 8; pp. 1780-1789.
Moudallal et al.; “Monoclonal antibodies as probes of the antigenic structure of tobacco mosaic virus”; EMBO Journal; 1982; vol. 1; pp. 1005-1010.
McGuinness et al.; “Class 1 outer membrane protein ofNeisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology”; Molecular Microbiology; 1993; vol. 7; pp. 505-514.
Greenspan et al.; “Defining epitopes: It's not as easy as it seems”; Nature Biotechnology; 1999; vol. 17; pp. 936-937.
Cruse et al.; Illustrated Dictionary of Immunology, 2nd ed.; 2003; pp. 46, 166, 382.
Bowie et al.; “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”; Science; 1990; vol. 247, No. 4948; pp. 1306-1310.
Bos Martine Petronella
Poolman Jan
Tefson Boris
Tommassen Johannes Petrus Maria
Coulter Kathryn L.
Gangle Brian J
GlaxoSmithKline Biologicals S.A.
Minnifield Nita M
University of Utrecht
LandOfFree
Outer membrane vesicles and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Outer membrane vesicles and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Outer membrane vesicles and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263513